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Abstract 
Objectives: Hereditary haemorrhagic telangiectasia (HHT) affects 1 in 5-8,000 
individuals. Pregnancy outcomes are rarely reported. The major reason is that most 
women do not have their HHT diagnosed prior to pregnancy.  Utilising a large well- 
characterised series, we studied all pregnancies known to have occurred in HHT-affected 
women, whether or not their diagnosis was known at the time of pregnancy.   Our aim 
was to estimate rates and types of major complications of HHT in pregnancy, to guide 
management decisions.  
 
Design: Cohort study, with prospective, retrospective and familial components. 
 
Setting/ Population: Tertiary referral centre population  
 
Methods: All 262 pregnancies in the 111 women with HHT and pulmonary 
arteriovenous malformations (PAVMs) reviewed between 1999 and 2005 were studied.  
82 (74%) did not have a diagnosis of HHT/PAVM at the time of pregnancy.  222 
pregnancies in their 86 HHT-affected relatives were also studied.   
 
Main outcome measures: Maternal death, haemoptysis, haemothorax, stroke. 
Results:  Thirteen women experienced life-threatening events during pregnancy: 1.02% 
(95% confidence intervals 0.13, 1.92%) of pregnancies resulted in a major PAVM bleed; 
1.24% (0.25, 2.23%) in stroke (not all were HHT-related); and 1.00% (0.13, 1.92%) in 
maternal death.   All deaths occurred in women previously considered well.  In women 
experiencing a life-threatening event, prior awareness of HHT or PAVM diagnosis was 
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associated with improved survival in women experiencing a life-threatening event 
(p=0.041, Fisher's exact test).   
 
Conclusions: Most HHT pregnancies proceed normally. Rare major complications, and 
improved survival outcome following prior recognition, means that pregnancy in a 
woman with HHT should be considered high risk. Recommendations for pregnancy 
management are provided.    
 
 
 
 
Key words: nose bleeds, arteriovenous malformations, haemorrhage, pulmonary, 
cerebral, myocardial infarction 
 
 
 
Introduction 
Hereditary haemorrhagic telangiectasia (HHT, Osler-Weber-Rendu syndrome), is a 
relatively common genetic condition affecting 1 in 5-8,000 Europeans 
1, 2
.  Most affected 
individuals are unaware of their diagnosis 
3, 4
.  This is particularly true of younger 
individuals since the main clinical manifestations of recurrent nosebleeds, characteristic 
mucocutaneous telangiectasia and anaemia are either considered normal (nosebleeds), or 
become prominent later in life 
5, 6
.  HHT-affected individuals also commonly have silent 
arteriovenous malformations (AVMs). Screening programmes in asymptomatic 
individuals indicate that these occur at significant frequencies.  Pulmonary AVMs are 
now estimated to affect at least 48% of HHT patients 
7
; cerebral AVMs up to 10% 
8
; 
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hepatic AVMs approximately 30% 
9
, with spinal AVM frequencies estimated at between 
0.3-1%.   
 
In normal pregnancy, complex physiological vasodilatory responses are associated with 
the increase in cardiac output that approaches 50% by the end of the second trimester 
10
.  
Cardiac chamber 
10
 and aortic 
11
 dimensions increase in normal pregnancies.   Effects on 
the HHT vascular bed would be predicted. 
 
Two series of pregnancy outcomes in HHT have been reported.  Goodman et al 
performed a retrospective study of 40 HHT patients (recruited from an ENT clinic) 
compared to 80 controls matched for age, ethnicity, religion and health care 
12
. The rates 
of miscarriage per pregnancy (14.4% versus 9.9%, HHT figures given first), and 
abnormal outcome per individual (50% versus 42.3%) did not differ statistically between 
the two groups.  In a retrospective series of 161 pregnancies in HHT-affected women and 
family members recruited from a clinic with a PAVM bias, no excess rate of miscarriage 
was reported 
13
.  There was a significant increase in maternal complications in women 
with PAVMs: overall, 2 maternal deaths (PAVM haemorrhage), 6 cases of PAVM shunt 
deterioration and three maternal strokes were reported 
13
.   
 
In addition to these series, there have been case reports of HHT complications during 
pregnancy: Pulmonary AVM-related haemorrhage 
14-20
, and growth of pulmonary AVMs 
13, 15, 16, 21, 22
 have been reported during pregnancy.  HHT-related cerebral AVMs have 
presented or haemorrhaged in the third trimester 
23-25
.  It is recognised however, that in 
pregnancy and in general, cerebral AVMs are associated with lower rates of haemorrhage 
25, 26
 than cerebral aneurysms, which affect 3% of the general population 
27
 and may be 
familial 
28, 29
.  
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Patient group websites (www.hht.org; telangiectasia.co.uk) mean many  
women with HHT are aware of HHT-specific pregnancy risks.  In contrast, most HHT 
pregnancies will be managed by obstetric teams with little personal experience of HHT, 
since HHT will affect only two in 10,000 women.  How should such teams place the 
recognised pregnancy-related risks in context for a healthy woman approaching 
pregnancy with a known diagnosis of HHT, and how should pregnancy management 
differ?   
 
In order to facilitate more informed management decisions, pregnancy outcomes were 
studied in our well-characterised 1999-2006 Hammersmith HHT/PAVM cohort. The 
statsistical power of studies on rare diseases such as HHT and PAVMs is difficult due to 
the relatively small number of affected patients (fewer than 450 reported in world 
literature prior to 1998; 27 referred to British Thoracic Society BOLD project between 
1999-2007).  Under these circumstances, utilisation of retrospective arms and novel 
statistical methods may be essential to ascertain an evidence base for clinical practice and 
research priorities, as recently reported by us for stroke, brain abscess and thrombotic 
complications  
3, 36
. 
 
Here we report an approach that allowed two major questions to be addressed:  First, 
whether estimates of absolute risks of pregnancy could be established; and second, 
whether recognition of at-risk status might improve outcome in the event of a life 
threatening HHT complication during pregnancy. The findings were utilised to develop 
recommendations for pregnancy management. 
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Methods 
Study setting and participants 
 
Analysis of patient records was approved by Hammersmith, Queen Charlotte’s, Chelsea, 
and Acton Hospital Research Ethics Committee (LREC 2000/5764). 
 
The study populations comprised the 205 consecutive men and women with HHT and 
pulmonary AVMs (from 181 different HHT families) who were reviewed in the 
Hammersmith Hospital PAVM clinical service between May 1999 and May 2005, 
followed up until May 2006.  A diagnosis of HHT was assigned according to the 
presence of at least three established international criteria, namely recurrent nosebleeds, 
mucocutaneous telangiectasia (Figure 1), visceral involvement, and family history 
30
:  All 
individuals were screened for the presence of pulmonary AVMs using imaging (thoracic 
CT scan unless the chest x-ray was diagnostic), and all individuals with pulmonary 
AVMs large enough for treatment  underwent coil embolization as described previously 
31
. In keeping with current recommended clinical practice in Europe, screening of 
asymptomatic individuals for the presence of cerebral 
32
 or hepatic 
9
 vascular 
malformations was not performed. 
 
Pregnancy groups 
While a prospective study was initiated, only 18 women had pregnancies following 
review by us.  Most pregnancies occurred in women prior to review. In the majority of 
these women, pregnancies occurred prior to PAVM diagnosis which in turn, was usually 
prior to the diagnosis of HHT 
3
.  In order to record life-threatening events that were less 
likely to have occurred in women who survived their pregnancies, we also studied the 
pregnancies of the women’s first degree relatives who were affected by HHT as denoted 
by recurrent nosebleeds, telangiectasia or other HHT complications.  222 pregnancies 
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occurred in these 86 HHT-affected women.  Again, the majority of pregnancies occurred 
prior to HHT/PAVM recognition.  Table 1 summarises the features of these three groups. 
 
 
Table 1 
Group Women Pregnancies HHT or PAVM diagnosis at time of 
pregnancy (%, proportion) 
Prospective 16 23 100% (23/23) 
Retrospective 97 239 8.3% (20/239) 
Relatives 86 222 5.4% (12/222) 
 
 
i) Prospective group: 
Women in the prospective group received intervention and pre-pregnancy advice that 
may have influenced pregnancy outcomes.  Fifteen underwent PAVM embolisation 
treatment prior to pregnancy.  In addition, pregnant women, their obstetric team, and 
local doctors were provided with advice developed following our earlier manuscript 
13
, 
and subsequent discussions.  This information advised of the small risk of haemoptysis to 
be considered a medical emergency if it occurred in pregnancy, and the potential 
presence of cerebral and spinal AVMs. We suggested that women with HHT were 
managed as though they had cerebral AVMs, noting that theoretical concerns, and 
evidence of rupture of cerebral AVMs and aneurysms during vaginal and Caesarean 
deliver, influence general obstetric anaesthetic practice 
33, 34
.  At our institution, a 
prolonged second stage of labour was avoided to minimise Valsalva manoeuvres, and if 
general anaesthesia was required, modified induction regimes with opiates were used to 
attenuate the hypertensive response to laryngoscopy.  Although the anaesthetic technique 
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was protective for the mother, placental transfer of opiate is well recognised and thus this 
was not ideal for the baby.  At our institution, we withheld regional analgesia/anaesthesia 
unless spinal AVMs had been excluded..  
 
Retrospective and relatives groups: 
Occurrence and outcome of all pregnancies were documented during a detailed personal 
history (retrospective group) or family history (relatives group). None of the women in 
these groups had received detailed information of possible pregnancy risks.  Where 
haemoptysis, stroke or maternal death had occurred, with consent from the proband, 
further information was obtained from the relevant medical, obstetric, radiological or 
pathology services.  Histopathology samples and original imaging were reviewed. 
 
Statistics 
Basic statistics and univariate analyses were performed using Prism 4 (Graph Pad 
Software Inc, San Diego):  Continuous variables were compared by two-sided Mann 
Whitney test, binary variables using Fisher’s exact test.  Fisher's exact test was used to 
test the null hypothesis that prior recognition of HHT/PAVM status did not affect 
outcome in the event of pregnancy-related haemorrhagic complications. Significance was 
assessed at false discovery rate (FDR)=0.05 level 
35
. 
 
 
Results 
Complications occurred in first (n=6), second (n=7) and third or greater (n=5) 
pregnancies, as summarised in Table 2. 
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Table 2 Maternal outcomes of 484 HHT pregnancies: 
 
 Prospective Retrospective Relatives Combined 
Pregnancies N 23 239 222 484 
Women N  16 97 86 199 
Maternal deaths N (%  pregnancies; 95%CI) 0 0  5 (2.3; 0.29, 4.2%) 5 (1.00; 0.13, 1.92%) 
PAVM haemorrhage N (% pregnancies; 95%CI) 2 (4.3; -4.7, 13.5%) 2 (0.84; 0.033, 2.0%) 2 (0.9; -0.35, 2.2%) 6 (1.36; 0.17, 2.54%) 
Strokes N (% pregnancies, 95%CI) 0 3 (1.3; -0.17, 2.7%) 3 (1.4; -0.18, 2.9%)† 6 (1.24; 0.25, 2.23) 
Myocardial infarction § N (% all pregnancies, 
95%CI) 
0 0 1 (0.45; -0.44, 1.4) 1 (0.21; -0.20, 0.61) 
Spinal haemorrhage 0 0 0 0 
Legend: N number, CI 95% confidence intervals, pregs pregnancies.  † Includes one peripartum event resulting in death during childbirth.  4 pulmonary 
haemorrhages in post partum period not included in table 
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Pulmonary AVM haemorrhage 
There were six PAVM haemorrhages in the prospective and retrospective groups, as 
detailed in Figure 2A, B. Four of these women had had previous PAVM embolization at 
four different institutions.  Two women were treated by embolization of pulmonary or 
systemic arterial supply to the PAVM, and two women underwent emergency 
thoracotomy for surgical resection or cauterisation of PAVMs.  Major haemoptysis was 
also reported in six relatives, leading to the two previously reported cases of maternal 
death 
13
, and two further fatalities in the first post partum year.   
 
Overall, the rate of life-threatening bleeds from pulmonary AVMs was 1.36% (0.17, 
2.54%) during pregnancy/delivery: events occurred in the second trimester (n=1), start of 
the third trimester (n=6), immediately post Cesarian section (n=1).   The rate of life-
threatening bleeds from pulmonary AVMs in the post partum year was 0.63% (95%CI -
0.08, 1.3%). These figures contrast with the full series of women 
3
 in which major 
haemoptysis affected only two outside of pregnancy, and there were no haemothoraces. 
 
 
 
Strokes in pregnancy 
There were three significant strokes during pregnancy in the patient group.  Two occurred 
in the first trimester, were of ischaemic aetiology and were attributed to paradoxical 
emboli through pulmonary AVMs 
3
 that were subsequently embolised.  A third was a 
subarachnoid haemorrhage as previously reported 
13
.  All women made good recoveries 
and the pregnancies subsequently proceeded normally. 
 
In relatives, three third trimester strokes were also reported. Two were fatal, one due to 
rupture of an internal carotid artery aneurysm at 7 months gestation (Figure 2C), and a 
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second due to undefined pathology during childbirth leading to maternal death.  A third 
resulted in a hemiplegic stroke in the 7
th
 month of pregnancy. An abnormal vessel was 
surgically resected after a Cesarean section under general anesthesia, and the woman 
went on to have a further uncomplicated pregnancy.   
 
 
 
Maternal death 
No maternal deaths occurred in the patient group comprising a small prospective group of 
23 pregnancies, and large retrospective group of 239 pregnancies for which survival was 
a prerequisite. In the relatives’ group which did not have this 'survival to review' bias, 
there were five deaths.  One was due to an acute transmural myocardial infarction in a 16 
year old at 32 weeks gestation (Figure 2D), two deaths were due to haemoptysis 
13
, and 
two were due to haemorrhagic strokes.  The overall maternal death rate was 1.00% of 
pregnancies (95% confidence limits 0.13, 1.92, Table 1); 2.51% (0.32, 4.71) of women.  
All deaths in our series occurred in women previously considered well and not under 
medical review for HHT.   
 
In the event of a life-threatening event, there was a statistically significant improvement 
in survival in women in whom the diagnosis of HHT or PAVMs had been made 
previously:  Of the 17 women with haemoptysis/haemothorax, stroke or myocardial 
infarction, five had a known diagnosis of PAVM (for haemoptysis) or HHT at the time, 
and all five survived with their infants.  Of the twelve other women, whose haemorrhagic 
complications during pregnancy occurred prior to the diagnosis of HHT or PAVMs, 
seven died and five survived (p =0.041 Fisher's exact test). 
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Discussion  
 
Between 1985 and 2005, all cause UK maternal mortality rates ranged from 0.010- 
0.014% 
38
.  Our data demonstrate that in HHT, while the vast majority of pregnancies 
proceed uneventfully, the mortality rate is significantly increased, due to PAVM 
haemorrhage, strokes and myocardial infarction.  Life-threatening events occurred in 
women who had few manifestations of HHT prior to pregnancy, but prior awareness of 
HHT/PAVM diagnosis was associated with a statistically improved survival outcome for 
mother (and infant) in the event of a major complication.  
 
The strengths of this study include large numbers examined for a rare condition: This is 
particularly important since it is not possible to ascertain HHT-related death rates from 
recent Confidential Enquiries into Maternal and Child Health (CEMACH) reports in 
which events would be classified as ‘other indirect’ causes of death 38.  Furthermore, 
most individuals with HHT are unaware of their diagnosis, and maternal death in 
pregnancy may be a precipitation for family review and referral. Previous small series are 
therefore likely to have over-represented maternal risks due to ascertainment bias, as in 
our previous pregnancy series 
13
.   However the overall types of complications are similar 
to those previously reported here, namely PAVM-related haemorrhage, and stroke. 
 
Potential biases present included referral bias (pregnancy complications in a relative 
biasing the referring physician towards referral), and the pulmonary AVM focus of our 
clinical practice.  In addition, in order to reduce bias due to intervention, or survival to 
review, it was essential to capture data in relatives in whom the diagnosis of HHT was 
made from a reported history or transmission to children.  This method is likely to have 
led to a failure to capture all affected individuals.  For these reasons, we suspect that the 
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overall risks of pregnancy may be revised downwards.  Importantly however, we are 
aware of three other relatively recent UK PAVM-haemorrhage deaths in pregnancy that 
were not captured by our series.).  
 
Many complications in the HHT pregnancies occurred in the second and third trimesters, 
at the time of reduced peripheral resistance and increased cardiac output, and reduced 
systemic vascular resistance 
10
.  Similar timings are observed in haemorrhages from non-
HHT cerebral AVMs 
27
.  We therefore anticipate that the haemorrhages in our population 
occurred as a result of general pregnancy responses leading to aberrant haemodynamic 
and other stresses in an abnormal vascular bed, as opposed to an HHT-specific response 
to pregnancy.   
 
The reported survival advantage of prior recognition of HHT/PAVM status is 
encouraging. We presume this operates by heightened patient and physician awareness of 
potential complications and novel symptoms.  While emergency intervention is likely to 
need to be managed on a case-by-case basis, prior recognition (and pre-planning of 
management in the event of a complication) may be sufficient for local obstetric services 
to optimise outcomes in the event of a rare complication, including emergency delivery 
where maternal survival is unlikely.   
 
 
The data allow some preliminary guidance for clinical management, which is summarised 
in Table 3.  In almost all cases in this series, and those known subsequently to us, there 
was sufficient time after the onset of symptoms to allow for hospital admission and 
intervention.  Thus all pregnancies with HHT should be considered high risk, and women 
should be advised about the small but serious risks, though re-assured that these appear 
less threatening where medical and obstetric services are aware of the complications.  
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Advice to all maternity health care providers needs to emphasise the need for immediate 
referral should haemoptysis or dyspnoea occur. 
 
In general for HHT-affected adults, screening and treatment of pulmonary AVMs is 
recommended to reduce later complications such as paradoxical embolic stroke and 
haemorrhage.  The management of asymptomatic women found to have pulmonary 
AVMs during pregnancy is not as clear-cut as for non-pregnant individuals.  During 
pregnancy, our data have shown that the risk of pulmonary AVM-associated 
complications is low; furthermore, there is no reported evidence that embolization of 
pulmonary AVMs during pregnancy in women who have not experienced a complication 
reduces the risk of haemorrhage or ischaemic stroke in the second and third trimester.  
The risks associated with PAVM embolization are small but the procedure does involve 
ionizing radiation and, as with any intervention, there is the potential for complications.  
For these reasons, we do not feel that PAVM screening and treatment of asymptomatic 
individuals during pregnancy is justified. 
 
 
Screening for cerebral AVMs could simplify obstetric anaesthetic management for the 
90% of individuals in whom no cerebral AVM or aneurysm would be detected, but there 
are several concerns. First, such scans may lead to false reassurance since small cerebral 
AVMs are not detectable by MRI, and pregnancy itself precipitates the growth of many 
AVMs such that pre or early-pregnancy assessment of AVM presence or size may not be 
relevant to the situation in late pregnancy or delivery.  Secondly, up to one in ten women 
will be found to have an asymptomatic cerebral AVM.  European risk-benefit analyses of 
treatment of asymptomatic cerebral AVMs in the general HHT population are not 
interpreted in favour of treatment 
33
.  The published literature, and our current data, do 
not suggest that pregnancy substantially alters these considerations.  Thus up to 10% of 
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women would be faced with the identification of cerebral AVMs for which treatment 
would not be recommended at the current time.  For any individual, it is difficult to judge 
how well they would cope with this knowledge 
40
.  Whether the obstetric anaesthetic 
considerations justify subjecting women in pregnancy to these concerns needs further 
informed discussion. 
 
Spinal AVMs in non-HHT individuals have been punctured by epidural needles resulting 
in paraparesis 
41
.  This has led some obstetric anaesthetic practices, including our own, to 
avoid regional anaesthesia, in turn, increasing the likelihood of a general anaesthetic. 
Were spinal AVMs to be excluded, epidurals could be employed with greater 
reassurance. Furthermore, in the unlikely event that spinal AVMs were detected, 
pregnancy management could be optimised to minimise risks of obstructed venous 
drainage, and since few bleeds have been reported, the associated anxiety would be 
substantially lower than for detection of a cerebral AVM.  
 
Table 3: Summary of recommendations for management of HHT pregnancies  
 
General 
 Consider all HHT pregnancies 'high-risk'; 
  
Advise that there are rare pregnancy-associated risks, but outcome is better if mother 
and obstetric services are pre-warned.   
  
Highlight any haemoptysis/severe dyspnoea as red flag symptoms to prompt 
immediate  hospital admission  
 
PAVMs 
 Pre-pregnancy screening† and treatment of PAVMs 
  No PAVM screening and treatment of asymptomatic individuals during pregnancy  
 
Cerebral haemorrhage 
 
For women with HHT with FH of cerebral haemorrhage or cerebral symptoms, 
cerebral MRI 
  For the majority of women with HHT, no cerebral MRI screen 
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Spinal AVMs 
 Exclude spinal AVMs by MRI scan during pregnancy to allow regional anaesthesia 
 
Delivery 
 Provide antibiotic prophylaxis during delivery ‡ 
  
Avoid prolonged second stage of labour in women in whom cerebral AVMs have not 
been excluded   
  
In the rare situations when general anaesthesia is required, use a modified induction 
regime utilising opiates  
Legend: †While discussion continues regarding the optimal mode of screening of individuals with HHT 39, 
a diagnosis can be made efficiently and quickly using a thoracic CT scan 
3
.  ‡ In keeping with general 
advice regarding dental and surgical procedures for individuals with PAVMs 
7
 and/or HHT 
3
  
 
 
 
In summary, our data indicate that the majority of HHT pregnancies proceed 
uneventfully, but that there are significant maternal risks.  Survival outcome may be 
improved by prior recognition of HHT/PAVM status. Recommendations for pregnancy 
management in individuals with HHT are discussed and proposed. 
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Legends for Figures 
 
Figure 1: Typical non-florid HHT telangiectasia on tongue and finger   
Telangiectasia are also commonly observed on the lips and oral mucosa. 
 
Figure 2: Maternal complications during pregnancy 
A) Case 1: Haemoptysis: Appearances of modest PAVM (arrowed).  B) Case 2: 
Haemothorax: Bi) lobectomy image of surface PAVM with 2cm diameter sac (arrowed) 
which ruptured. Bii) Histopathology of ruptured aneurysm, with point of rupture (narrow 
arrow) at lower border. Note region of  endothelial intimal fibrous proliferation (thick 
arrow) probably secondary to endothelial damage in these malformations.  C) Case 16: 
Haemorrhagic stroke: Cerebral CT scan of a 26 year old para 3 at 7 months gestation.  
Ci) CT scan demonstrates massive intraventricular haemorrhage with significant 
ventricular dilatation Cii) The causative partly calcified carotico-ophthalmic aneurysm in 
the anterior part of the circle of Willis (arrowed).  There was also cisternal blood 
supporting a herald subarachnoid bleed.  D) Case 17: Myocardial infarction. Post 
mortem cardiac histology: The dead myocytes (pink, anuclear cells) surrounded by 
neutrophils indicate a recent (within 48hs) acute transmural myocardial infarction.  There 
was accompanying pulmonary oedema and bilateral pleural effusions of 500mls. 
Coronary arteries displayed a hint of coronary atheroma but no narrowing or embolism.  
There was no evidence of vasculitis.  Sections of the right ventricle were normal. We 
speculate that an undiagnosed pulmonary AVMs contributed to her death, causing a 
paradoxical embolic coronary artery thrombosis which had dissipated at the time of death 
24 hours later:  HHT patients have a venous prothrombotic tendency via elevated Factor 
VIII levels 
37
, and pulmonary AVMs provide a conduit for paradoxical emboli.   
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